Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
The General Meeting of Shareholders of Oryzon, a clinical stage biopharmaceutical company focused on Epigenetics to develop therapies in oncology and ...
ORYZON Genomics has finalized the multiple ascending dose (MAD) stage of its Phase I clinical trial to evaluate the safety, tolerability and...
Oryzon today announced that it will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City. Held at the St....
Oryzon Genomics, an epigenetics-based biotechnology company focused on developing therapeutics in oncology and neurodegenerative diseases, will...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.